CordenPharma's agreement to acquire AmbioPharm, announced on 27 May 2026, adds two peptide API sites, approximately 400 employees, and Asia to its peptides platform. The combined business pairs Shanghai upstream synthesis with U.S. purification and lyophilization in North Augusta, South Carolina.…
CordenPharma's agreement to acquire AmbioPharm, announced on 27 May 2026, adds two peptide API manufacturing sites, approximately 400 employees, and a third continent to CordenPharma's peptides business. For a CDMO customer whose program depends on a long, difficult, or high-purity peptide, the meaningful question is not how much capacity the deal adds in the abstract. It is where the capacity sits, which stages of the manufacturing chain each site covers, and whether the combined synthesis platform can make hard sequences at commercial scale. The deal's practical shape: Shanghai brings upstream synthesis across solid-phase, liquid-phase, and hybrid routes. North Augusta, South Carolina is positioned as the downstream site, adding purification and lyophilization in the United States beside CordenPharma's existing Colorado peptide facility.
The transaction is an agreement, not a completed sale. It remains subject to customary closing conditions, financial terms were not disclosed, and no closing date was given. Everything that follows describes the intended state of the combined business, not the current one.
CordenPharma, a contract development and manufacturing organization owned by the private equity firm Astorg since 2022, has 11 facilities in Europe and North America and reported sales of €960 million in the 2025 financial year with more than 3,000 employees. Astorg manages more than €24 billion in assets under management. AmbioPharm, a U.S.-headquartered custom synthetic peptide CDMO founded in 2005, operates two manufacturing facilities: North Augusta, South Carolina, and Shanghai, China. Approximately 400 people work across the two sites.
| Facility | Location | Role in combined platform | Reported capabilities |
|---|---|---|---|
| North Augusta | South Carolina, USA | Downstream site; CordenPharma's second U.S. peptide facility | Purification, lyophilization; complements CordenPharma Colorado |
| Shanghai | China | Upstream synthesis site | SPPS, LPPS, hybrid synthesis; selected downstream steps; intended for clinical and commercial global supply |
The North Augusta site will become CordenPharma's second U.S. peptide facility, after the Colorado operation, and is described as adding purification and lyophilization capacity. Shanghai is described as housing a newer peptide facility with upstream capacity for solid-phase, liquid-phase, and hybrid synthesis plus selected downstream steps, intended to support both clinical and commercial global supply. After integration, CordenPharma's Peptides Platform will span three continents: Europe, North America, and Asia.
AmbioPharm manufactures new chemical entities NCEs as peptide APIs under cGMP for clients worldwide, and its facilities have been inspected by the U.S. FDA and other global regulators, according to the company. AmbioPharm's shareholders will reinvest in the combined business after the acquisition, and BNP Paribas acted as exclusive financial advisor to AmbioPharm. The announcement quoted Dr. Michael Quirmbach, president and CEO of CordenPharma; Brian Gregg, CEO of AmbioPharm; Antoine Thomas, a director at Astorg; Paul Perreault, chairman of CordenPharma's board; and Ling Yang, partner and head of healthcare at Carlyle Asia, an investor in AmbioPharm. Executives at Astorg and Carlyle said they expect the peptide CDMO market to keep growing; the announcement provides no market forecast or utilization data of its own. Those statements are expectations, not commitments.
The chemistry explains why this deal is about more than floorspace. Most peptide APIs are made by solid-phase peptide synthesis SPPS : the chain is assembled one residue at a time on an insoluble resin, with each cycle requiring deprotection of the growing chain's N-terminus, activation and coupling of the next amino acid, and washes. Each coupling is never quite complete. For a short peptide, the small fraction of chains that failed to couple at any step is removed easily during purification. For a long peptide, the arithmetic changes. A synthesis of 50 residues at a 99.5% per-coupling yield leaves a substantial fraction of chains with one or more missing residues, and every deletion or truncation product differs from the full-length product by a single residue. As the chain grows, the chromatographic separation between target and near-target impurities shrinks, and purification becomes the dominant cost and yield driver.
Beyond stepwise yield, long sequences fail on the resin for physical reasons. Growing chains can aggregate or fold, blocking access to the reactive terminus, and difficult sequences form secondary structures that stall coupling. Deletion impurities are not the only threat to quality. Side reactions target specific residues: methionine and cysteine can oxidize, asparagine and glutamine can deamidate, and sequences containing aspartic acid or asparagine are prone to aspartimide formation, a cyclization that racemizes and can lead to chain cleavage. When the API's structure requires disulfide bonds, they must be formed selectively and in the correct pairing. For a therapeutic peptide, the related-substance profile is a regulatory matter, not only a manufacturing nuisance. Regulators expect the manufacturer to identify, quantify, and control impurities, and acceptance criteria tend to tighten as a program moves from clinical to commercial supply. More chromatographic resolution and more lyophilizer time translate directly into an ability to meet tighter purity specifications.
This is why peptide manufacturers turn to alternative routes for the class of molecules this deal targets. Liquid-phase peptide synthesis LPPS builds the chain in solution. It allows purification at intermediate steps rather than only at the end, which is valuable for short segments or sequences that misbehave on resin, at the cost of more handling and higher solvent use. Hybrid approaches make fragments by SPPS and assemble them by LPPS or solution-phase coupling. Fragment-based synthesis is the standard answer to very long peptides: instead of one linear chain of 60 or 80 residues, the manufacturer builds protected segments of 10 to 20 residues and joins them convergently. That shortens the longest linear assembly and cuts the number of steps where errors accumulate, but it introduces problems of its own. Protected fragments can be poorly soluble, and activation of a fragment's C-terminal residue is a well-known site of epimerization, the loss of chiral integrity at the alpha carbon. A fragment strategy is therefore not a simple workaround; it is a set of engineering decisions about segment length, coupling chemistry, protecting groups, and where the joins occur.
Tag-assisted synthesis is a further response to these failures. A solubilizing tag is attached to the growing chain to keep it in solution or aid its isolation, then removed after assembly. CordenPharma's TAPS Tag-Assisted Peptide Synthesis is its named variant of this approach, and the company lists it as part of the combined platform. The general principle is well established: tags that improve solubility or enable a non-chromatographic isolation step can rescue sequences that aggregate or are hard to purify. The announcement gives no technical details of how TAPS performs on specific sequences, so buyers should treat it as a route option to be evaluated on their own molecule, not as a guarantee.
The downstream half of the chain is where high purity is actually delivered. Preparative reversed-phase HPLC separates the full-length product from deletion, truncation, and epimer impurities. The resolving power needed rises steeply with chain length and with the hydrophobicity of the product. Lyophilization, the final drying step that produces the stable solid peptide API, is capacity-intensive: it is slow, and lyophilizer shelves are a common bottleneck in peptide CDMOs. The North Augusta site's stated role, purification and lyophilization in the United States, addresses exactly this part of the process. Shanghai's relative strength, per the announcement, is upstream synthesis.
| Approach | Principle | Where it fits | Main limitation |
|---|---|---|---|
| SPPS | Stepwise assembly on a solid resin | Routine peptides; standard for most APIs | Error accumulation and aggregation in long chains |
| LPPS | Assembly in solution with intermediate purification | Short segments; difficult sequences | More steps and higher cost |
| Hybrid | SPPS fragments joined in solution phase | Mid-length and difficult peptides | Solubility and handling complexity |
| Fragment-based | Convergent joining of protected segments | Very long peptides, roughly 40 residues and up | Epimerization and solubility at the joins |
| Tag-assisted | Solubilizing or isolation tag on the chain | Aggregation-prone or hard-to-purify sequences | Tag removal and extra steps |
The synthesis-approach table is based on the general chemistry, not on the acquisition announcement, which names these methods but does not describe how they will be deployed on specific molecules.
For a buyer of peptide API services, the acquisition changes the menu of options in four concrete ways.
First, geography. A program can be placed at a U.S. site, in Europe across the existing 11-site network, or in Shanghai. The stated intent is that customers get a choice of manufacturing lines, scale-up paths, and regional or global supply models. For products destined for U.S. trials or markets, a U.S. downstream site with purification and lyophilization reduces reliance on cross-border finishing steps. For programs that want a lower-cost upstream synthesis site, Shanghai offers that without forcing the customer to take final processing there.
Second, the upstream-downstream split. The two facilities are complementary in the narrow sense that each is described as strong where the other is light: Shanghai on synthesis, South Carolina on purification and drying. That allows a customer to run SPPS in Shanghai and finish in North Augusta, or to keep everything in one region. It does not mean every project can be split that way. Process transfer between sites is itself a project: analytical methods must be comparable, the purification method must be validated at the receiving site, and the regulatory dossier must be updated with the new site of manufacture. Cross-border programs add their own logistics: transport of protected intermediates, customs, export control, and the time and cost of shipping material from Shanghai to South Carolina with the required stability and cold-chain conditions. These problems are solvable, but they should be priced into a campaign plan from the start.
Third, route options. The combined platform lists linear and fragment-based approaches using SPPS, LPPS, hybrid synthesis, and TAPS. A customer with a 60-residue, aggregation-prone peptide is no longer limited to whichever single route a given site has mastered. The practical question to ask is not whether a CDMO owns the technology names, but which route a specific site has run at commercial scale, for a peptide of comparable length, and with what purity profile.
Fourth, continuity and redundancy. AmbioPharm already manufactures cGMP NCE peptide APIs for global clients and reports a history of FDA and other regulatory inspections. The NCE designation matters: these are proprietary molecules under development, not generic copies of an originator product, and supporting them requires route development and process characterization from the molecule's early stages. Existing clients should expect their programs, quality systems, and regulatory filings to carry into the combined business, but no integration plan has been published. A second U.S. site also creates a redundancy option, but only if the process is actually validated at both sites, which requires duplicate analytical methods, comparability data, and regulatory filings. Two sites are an option, not an automatic safety net. Buyers with active contracts should ask, in writing, how a change of ownership affects their quality agreement, site registrations, and confidentiality terms.
Practical guidance for a buyer evaluating this combined platform:
For buyers, the phrase "end-to-end support from clinical phases through commercialization" means the combined business intends to take a peptide from first synthesis to commercial supply. Whether that works in practice depends on integration details that have not been announced.
The limits of the announcement matter as much as its content. The financial terms are undisclosed. No closing date or timeline was given, and the transaction is subject to customary closing conditions. Whether the deal requires regulatory approval from U.S., Chinese, or other authorities is not specified. The announcement also does not say whether foreign investment review applies in either jurisdiction; nothing indicates such review is pending, and nothing rules it out.
Several operational questions are open. How Shanghai will be integrated into CordenPharma's European and U.S. network, whether the AmbioPharm brand and leadership continue after closing, what ownership stake AmbioPharm's shareholders hold after reinvesting, and how the added capacity changes pricing and competition in peptide CDMO supply are all unstated. The shareholder reinvestment and the Astorg and Carlyle statements of confidence suggest the sellers expect the peptide market to keep growing, but the announcement contains no data on market size, utilization, or order books. The peptide CDMO market is fragmented, and consolidation can shift pricing leverage; any reduction in independent capacity can affect lead times and price negotiations, and buyers with multi-year contracts should watch how the market responds.
The descriptions of the Shanghai facility as new and of AmbioPharm's inspection history as having "excellent" outcomes are company characterizations in the announcement, not independent findings. A buyer should verify inspection history directly with the relevant agencies.
What would resolve these questions: the closing announcement with terms and conditions, regulatory filings in the United States and China, a published integration plan naming site roles and leadership, and eventually inspection reports and capacity disclosures from the combined company. Until then, the accurate summary of this deal is that CordenPharma has agreed to buy a two-site, approximately 400-person peptide CDMO, that the combination is designed to pair Shanghai synthesis with U.S. purification and lyophilization, and that the third continent and second U.S. site will exist only once the transaction closes. Customers who plan around the combined platform should have a documented fallback if it does not.
Vendors referenced: Purity Peptides.
Related reading: Peptide Purification Bottlenecks and PEC 2.0 Solutions, Reducing Benzotriazole and Solvent Hazards in Peptide Synthesis, Peptide Chirality as a Tuning Lever for Polyelectrolyte Complexes, Automated Peptide Synthesis: A Practical Getting-Started Guide.